A Study to Evaluate the Safety and Effectiveness of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta, and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients with Metastatic Ocular Melanoma and Previously Treated Patients with Unresectable Stage III/IV Cutaneous Melanoma

Overview

About this study

The purpose of this study is to determine the safety profile and maximum tolerated dose (MTD) of VSV-IFNß-TYRP1 therapy when administered by IV and IT injection in patients with previously treated metastatic melanoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic (Stage IV) melanoma, including metastatic ocular melanoma, with estimated largest tumor diameter ≤ 5cm and ≤ 2 tumors ≥ 3 to ≤ 5 cm diameter.
  • Cutaneous melanoma patients only:
    • At least one prior FDA approved systemic therapy in the metastatic setting; and disease progression after immune checkpoint inhibitors.
    • If tumor is BRAF-mutated, previous BRAF- and/or MEK-targeted therapies are required.
      • NOTE:  For ocular melanoma patients no current standard of care exists, so patients are permitted to be treated in1st line setting.
  • Measurable disease by any imaging modality as defined by RECIST (version 1.1).
    • NOTE: Disease that is measurable by physical examination only is not eligible.
  • Injectable disease (i.e., suitable for direct injection or through the use of ultrasound guidance) defined as:
    • At least 1 injectable and safely accessible cutaneous, subcutaneous, or nodal melanoma lesion ≥5 mm in longest diameter for metastatic cutaneous or mucosal melanoma;
    • At least one safely accessible liver metastasis for patients with metastatic ocular melanoma.
  • Patients with metastatic ocular melanoma must meet all of the additional inclusion criteria:
    • No more than 25% overall tumor involvement of the liver by MRI imaging;
    • Child Pugh Score A;
    • Absence of ascites;
    • No portal vein thrombosis.
  • Have resolution of all previous treatment-related toxicities to Grade 1 severity or lower.
  • The following laboratory values obtained ≤ 14 days prior to registration:
    • Absolute neutrophil count (ANC) ≥ 1500/mm^3;
    • Platelet count ≥ 100,000/mm^3;
    • Hemoglobin ≥ 9.0 g/dL (without need for hematopoietic growth factor or transfusion support);
    • Alanine aminotransferase (ALT) ≤ 2.5 x ULN;
    • Aspartate transaminase (AST) ≤ 2.5 x ULN;
    • Total bilirubin ≤ 1.5 x ULN;
    • PT ≤ 1.5 x ULN (or international normalization ratio [INR] ≤ 1.4) or PTT/aPTT ≤ULN;
    • Serum creatinine within institutional limits of normal (≤ ULN).
  • Life expectancy of ≥ 12 weeks.
  • ECOG Performance Status (PS) 0 or 1.
  • Willing and have the ability to comply with scheduled visits (including geographical proximity), treatment plans, laboratory tests, and other study procedures.
  • Willing to provide all biological specimens as required by the protocol.
  • Including fresh tissue for biomarker analysis (metastatic melanoma cohort with accessible injectable lesions only).
    • NOTE: Patients with cutaneous melanoma and accessible cutaneous/ subcutaneous lesions will have one lesion biopsied prior to the subject receiving the first dose of study treatment on Day 1 of Cycle 1 and the biopsy will be repeated on the injected target lesion and an uninjected lesion where possible post-virus treatment on Day 3.
    • NOTE: Repeat samples may be required if adequate tissue is not obtained.
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only.
    • NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Willing to use an adequate method of contraception (see Appendix III) from the first dose of study medication through 120 days after the last dose of study medication, for persons of childbearing potential or persons able to father a child only.

Exclusion Criteria:

  • Known standard therapy for the patient’s disease that is potentially curative or definitely capable of extending life expectancy.
  • Any of the following prior therapies:
    • Prior chemotherapy ≤ 2 weeks prior to registration;
    • Prior immunotherapy (monoclonal antibodies) ≤ 3 weeks prior to registration;
    • Prior experimental agent ≤ 2 weeks prior to registration;
    • Prior radiation therapy ≤ 2 weeks prior to registration.
  • Need for concurrent chemotherapy, immunotherapy, radiotherapy, ablation therapy or any ancillary therapy considered investigational (used for a non-FDA approved indication or in the context of a research investigation).
  • Minor surgical or interventional procedure ≤ 7 days prior to registration.
  • Major surgical procedure ≤ 21 days prior to registration.
  • History or evidence of melanoma associated with immunodeficiency states (e.g., hereditary immune deficiency, organ transplant, or leukemia, requires concomitant treatment with immunosuppressive agents, including CTLA-4 agonists, or chronic oral or systemic steroid medication including physiological replacement doses for adrenal insufficiency.
  • History of or plan for splenectomy or splenic irradiation.
  • History or evidence of central nervous system (CNS) metastases.
  • Active skin lesions (open wounds, severe rash, herpetic lesions, etc.).
  • Prior non-oncology vaccine therapies used for the prevention of infectious disease ≤ 28 days prior to registration.
  • Requires concomitant treatment with therapeutic anticoagulants.
  • Known history of active tuberculosis.
  • Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • Known acute or chronic hepatitis B or hepatitis C infection (requires negative test).
  • Metastatic ocular melanoma patients only: liver radioembolization ≤ 90 days prior to registration.
  • No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 35 years of registration.
    • NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 3 years prior to registration.
  • No uncontrolled intercurrent illness including, but not limited to:
    • ongoing or active infection;
    • symptomatic congestive heart failure;
    • unstable angina pectoris;
    • uncontrolled symptomatic cardiac arrhythmia;
    • uncontrolled hypertension (defined as blood pressure >160/90).
  • New York Heart Association classification III or IV, known symptomatic coronary artery disease or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias.
  • Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology.
  • Pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment.
  • Person of childbearing potential who is unwilling to use two (2) highly effective methods of contraception during study treatment and through 120 days after the last dose of study treatment.
  • Person able to father a child who is unwilling to use a highly effective method of contraception during study treatment and through 120 days after the last dose of study treatment.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Roxana Dronca, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Block, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20455118

Mayo Clinic Footer